Low urgency

Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661

Detected July 16, 2026 · in Pharmacy & Controlled Substances

FDA extends the effective date for the final resolution of DESI 7661 regarding estrogen-androgen fixed-combination drug products, delaying any potential market removal or labeling changes.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmacies and dispensers of estrogen-androgen fixed-combination drug products should confirm how it applies to their specific situation before acting. There is a time constraint attached: None at this time. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

The effective date for the final resolution of DESI 7661 has been extended, postponing any required actions such as product discontinuation or labeling updates.

Who it affects

Pharmacies and dispensers of estrogen-androgen fixed-combination drug products

What you must do

No immediate action required; monitor for future updates.

Deadline

None at this time

Source: https://www.federalregister.gov/documents/2026/06/26/2026-12933/drugs-for-human-use-drug-efficacy-study-implementation-estrogen-androgen-fixed-combination-drug

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances